Cost-effectiveness of hepatitis B vaccine immunization program in control of acute hepatitis B in Beijing, 1992-2013
HUANG Lie-yu1, HONG Bao-lin1, LYU Min2, GUO Yi-wei1, WANG Xi1, WANG Zong-wu3, SHI Xue-feng1
1.Management School, Beijing University of Chinese Medicine, Beijing 100029, China; 2.Beijing Center for Disease Control and Prevention, Beijing 100013, China; 3.Health Newspaper Office, Beijing 100027, China
Abstract:Objective To evaluate the cost-effectiveness relationship between the reported incidence of acute hepatitis B and the total cost of hepatitis B vaccine immunization program in Beijing from 1992 to 2013. Methods The total cost of hepatitis B vaccine immunization program in Beijing from 1992 to 2013 was considered as the cost indicator, and then we conducted the cost-effectiveness analyses based on the incidence of acute hepatitis B, mainly including the analyses of cost, incremental cost-effectiveness ratio and marginal effectiveness. Results The total cost of immunization with hepatitis B vaccine in Beijing in 1992-2013 went up, and the proportion of manpower cost also increased. With the increment of total cost of hepatitis B vaccine immunization program, the reported incidence of acute hepatitis B rose first and then declined, decreasing from 3.58/100,000 in 1992 to 1.34/100,000 in 2013. The incremental cost-effectiveness ratio for the duration from 1999 to 2005 was better. Conclusions The changes of the cost of immunization with hepatitis B vaccine in Beijing in 1999-2013 accorded with the actual development of society. The fluctuation of the reported incidence of acute hepatitis B might be related to the increase of hepatitis B virus carriers in migrants, the variation in the infectious disease reporting regulation, the introduction of new hepatitis B diagnostic criteria, and the optimization of institutional investment. Although the reported incidence of acute hepatitis B declines with the increase of the cost of immunization with hepatitis B vaccine, the optimal result has not yet appeared. The follow-up evaluation of hepatitis B vaccine immunization program should be conducted and the prevention and control strategy should be adjusted based on the actual situation.
黄烈雨, 洪宝林, 吕敏, 郭艺玮, 王溪, 王宗武, 石学峰. 北京市1992—2013年乙肝疫苗免疫规划对急性乙肝成本效果分析[J]. 实用预防医学, 2019, 26(12): 1437-1440.
HUANG Lie-yu, HONG Bao-lin, LYU Min, GUO Yi-wei, WANG Xi, WANG Zong-wu, SHI Xue-feng. Cost-effectiveness of hepatitis B vaccine immunization program in control of acute hepatitis B in Beijing, 1992-2013. , 2019, 26(12): 1437-1440.
[1] James SD, Anna SFL, Andrew KB, 等.Sherlock肝胆病学[M].第12版.北京:人民卫生出版社, 2014:333-337. [2] Cui F, Shen L, Li L, et al.Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China[J].Emerg Infect Dis, 2017, 23(5): 765-772. [3] 王怀, 高培, 陈维欣, 等.北京市2005—2014年急性乙型肝炎发病特征及病例复核结果分析[J].中华预防医学杂志, 2016, 50(9):815-819. [4] 张永强,李刚,高燕琳,等.2013年北京市传染病死亡负担分析[J].实用预防医学,2018,25(2):162-164. [5] 石诗雯.北京市乙型肝炎疫苗免疫成本分析[D].北京:北京中医药大学, 2017. [6] 龚晓红,王富珍,李辉,等.北京市1990—2003年急性乙型肝炎疫情报告病例的流行病学分析[J].中国自然医学杂志, 2006, 8(3):181-183. [7] 蒋艳.北京市卫生总费用核算数据处理的若干技术问题的研究[D].北京:北京中医药大学, 2014. [8] Alastair MG, Philip MC, Jane LW, et al.Applied methods of cost-effectiveness analysis in health care[M].UK: Oxford University, 2011:1-20. [9] 吴疆,贺雄,郑群.北京市1990—1997年肝炎分型及其流行状况的分析[J].疾病监测, 1999, 14(1):8-12. [10] 于淑丽.乙型肝炎免疫接种策略的评价[D].上海:复旦大学, 2003. [11] 单芙香,刘刚.深圳市乙肝疫苗免疫效果及成本效益分析[J].中国公共卫生, 2009, 25(4):489-490. [12] Shimakawa Y, Seck A, Nayagam S, et al.Screening strategies to prevent mother-to-child transmission of hepatitis B in sub-Saharan Africa[J].Lancet Gastroenterol Hepatol,2018, 3(4):222-223. [13] He J, Gu D, Wu X, et al.Major causes of death among men and women in China[J].N Engl J Med, 2005, 353(11):1124-1134. [14] 党如波,张顺祥,张卫东,等.中国新生儿乙肝疫苗免疫效果评估[J].中国公共卫生, 2009, 25(4):385-387. [15] 北京市统计局.2018年北京统计年鉴[M].北京: 中国统计出版社, 2018:1-30. [16] 马晓华.中国疾控中心:政策应推动疫苗研发[N].第一财经日报, 2011-05-25(A05). [17] 李黎,崔富强,张国民,等.乙型肝炎诊断标准(WS 299-2008)解读[J].中华预防医学杂志, 2014, 48(9):758-761. [18] 崔富强,王富珍,吴振华,等.中国2005—2010年报告乙型病毒性肝炎发病分析[J].中国疫苗和免疫,2011,17(6):483-486,559. [19] 王丹,白倩,石诗雯,等.北京市1992—2013年乙型肝炎计划免疫成本的调查研究[J/OL].中国预防医学杂志:1-4[2019-04-01].http://kns.cnki.net/kcms/detail/11.4529.R.20181119.1638.014.html. [20] 解洪涛,陈利伟,庄佳强.鲍莫尔“成本病”与“以药养医”:中国社会医疗成本快速增长[J].公共管理学报, 2015, 12(1):84-93,156-157. [21] WHO.Global health sector strategy on viral hepatitis, 2016-2021: towards ending viral hepatitis[EB/OL].(2016-06)[2019-04-01].http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/.